Table 1.

Cox proportional hazards regression analysis for associations with DMFS in IBE and IBD tumors

UnivariableMultivariable
VariablesaHR (95% CI)bPcHR (95% CI)P
IBE
 IMM (PID, WID, FID)0.46 (0.38–0.55)<0.00010.49 (0.39–0.61)<0.0001
 Histologic grade (I, II, III)1.00 (0.77–1.30)0.99
 Tumor size (T1, T2, T3)1.20 (0.93–1.54)0.161.37 (1.02–1.84)0.04
 LN status (−, +)1.41 (1.05–1.88)0.03
 Age (≤40 y, >40 y)0.95 (0.64–1.43)0.82
 ER status (+, −)1.15 (0.86–1.53)0.34
 Adjuvant treatment (no, yes)0.88 (0.67–1.13)0.31
IBD
 IMM (PID, WID, FID)1.07 (0.89–1.28)0.47
 Histologic grade (I, II, III)2.23 (1.76–2.84)<0.00012.14 (1.65–2.76)<0.0001
 Tumor size (T1, T2, T3)1.57 (1.24–1.99)0.00031.61 (1.18–2.20)0.003
 LN status (−, +)1.62 (1.21–2.16)0.0022.50 (1.44–4.31)0.001
 Age (≤40 y, >40 y)0.49 (0.33–0.74)0.002
 ER status (+, −)0.49 (0.35–0.68)<0.0001
 Adjuvant treatment (no, yes)0.89 (0.68–1.16)0.390.56 (0.33–0.96)0.03
  • Abbreviations: ER, estrogen receptor; LN, lymph node.

  • aEntered as semi-continuous variables: IMM (PID, WID, and FID) as 1, 2, or 3; histologic grade (I, II, III) as 1, 2, or 3; tumor size (T1, T2, and T3) as 1, 2, or 3; LN status (−, +) as 0 or 1; age (≤40 years, >40 years) as 0 or 1; ER status (+, −) as 0 or 1; adjuvant treatment (no, yes) as 0 or 1.

  • b95% confidence interval (CI).

  • cLikelihood ratio test P value.